Pioneer Pharmaceuticals Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Pioneer Pharmaceuticals Inc.
Singapore’s MerLion Completes Phase II Finafloxacin Urinary Tract Infection Trial Recruitment
The Singapore-based firm continues to push ahead on new applications for its finafloxacin antibiotic even as it searches for more funding to carry out work that can bring about regulatory approvals and cash flow.
Singapore’s MerLion Completes Phase II Finafloxacin Urinary Tract Infection Trial Recruitment
The Singapore-based firm continues to push ahead on new applications for its finafloxacin antibiotic even as it searches for more funding to carry out work that can bring about regulatory approvals and cash flow.
Singapore’s MerLion Completes Phase III Finafloxacin Studies For Outer Ear Infection, Looks Ahead To Other Indications
Singapore-based MerLIon Pharmaceuticals has reached another milestone with its finafloxacin antibiotic with the topic form for outer ear infection successfully passing Phase III trials in North America. But the firm is still looking for help taking another indication into Phase III.
Singapore’s Merlion Seeks Further Licensing Deals After Bolster By U.S. FDA QIDP QIDP Status
Singapore’s MerLion Pharmaceuticals received a boost for its intravenous and oral antibiotic finafloxacin following U.S. FDA designation as a Qualified Infectious Disease Product .The designation opens up exclusive marketing rights for as long as 10 years if the candidate successfully completes Phase III trials.
Company Information
- Industry
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice